NCT03613168View on ClinicalTrials.gov

Trastuzumab in HER2-positive Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

November 1, 2020

Study Completion Date

January 4, 2021

Conditions
CholangiocarcinomaBiliary Tract CancerHER-2 Protein OverexpressionHER-2 Gene Amplification
Interventions
DRUG

Trastuzumab

Trastuzumab plus gemcitabine/cisplatin

Trial Locations (1)

05505

Asan Medical Center, Seoul

All Listed Sponsors
lead

Changhoon Yoo

OTHER

NCT03613168 - Trastuzumab in HER2-positive Biliary Tract Cancer | Biotech Hunter | Biotech Hunter